Investigational IL-17A antagonist in the treatment of psoriatic arthritis - a review

Abstract

Introduction: The global burden of psoriatic arthritis (PsA) is considerable, with major effects on both quality of life and life expectancy. Approximately 40–50% of patients do not achieve the established therapeutic targets. Challenges related to tolerance, compliance, and therapeutic escape persist.

Areas covered: This study is a comprehensive review of the current literature analyzing the central role of interleukin-17 (IL-17) in the pathogenesis of PsA and emphasizing current and investigational therapies for IL-17A blockade.

Expert opinion: The current stage of development and expansion of IL-17A antagonists encompasses the third generation of such molecules. This generation includes small, injectable molecules such as sonelokimab and izokibep; oral molecules; and bispecific monoclonal antibodies. This approach is purported to facilitate enhanced tissue diffusion, augmented efficacy in refractory forms, and simplified utilization. The future of PsA treatments is contingent upon the implementation of precision medicine. The overarching objective is no longer to treat to target, but rather to treat to intercept, while ensuring the highest rate of control and tolerance for the patient.

Metadata

Item Type:	Article
Authors/Creators:	Osunbor, O. Nkeck, J.R. Adebajo, A.O. https://orcid.org/0000-0001-7368-7083
Copyright, Publisher and Additional Information:	© 2026 The Authors. Except as otherwise noted, this author-accepted version of a journal article published in Expert Opinion on Investigational Drugs is made available via the University of Sheffield Research Publications and Copyright Policy under the terms of the Creative Commons Attribution 4.0 International License (CC-BY 4.0), which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ © 2026 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/),which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.
Keywords:	Bispecific monoclonal antibodies; interleukin 17A antagonists; psoriatic arthritis; small molecules; third generation
Dates:	Submitted: 17 December 2025 Accepted: 24 July 2026 Published (online): 29 July 2026 Published: 29 July 2026
Institution:	The University of Sheffield
Academic Units:	The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > School of Medicine and Population Health
Date Deposited:	01 Sep 2026 08:55
Last Modified:	01 Sep 2026 08:55
Status:	Published
Publisher:	Taylor & Francis
Refereed:	Yes
Identification Number:	10.1080/13543784.2026.2710840
Related URLs:	PubMed URL
Sustainable Development Goals:
Open Archives Initiative ID (OAI ID):	oai:eprints.whiterose.ac.uk:244922

CORE (COnnecting REpositories)

Investigational IL-17A antagonist in the treatment of psoriatic arthritis - a review

Abstract

Metadata

Downloads

Accepted Version

Published Version

Export

Statistics